Pinealon

Overview

Pinealon is a synthetic tripeptide composed of L-glutamic acid, L-aspartic acid and L-arginine (sequence shorthand EDR). It is a member of the Khavinson family of short bioregulatory peptides developed at the St Petersburg Institute of Bioregulation and Gerontology, sharing the family's theoretical framework: short peptide sequences derived from tissue extracts that act as gene-regulatory signals selective for the tissue of origin.

Whereas Epitalon (AEDG) was derived from the pineal polypeptide epithalamin and is studied for telomere and pineal-axis effects, Pinealon has been positioned in the Khavinson programme as a more directly neurotropic short peptide — investigated principally for neuronal survival under stress, antioxidant gene expression and cognitive preservation in aged rodents.

International independent research on Pinealon is more limited than on Epitalon, and most published work comes from the same St Petersburg research group. This page summarises what is in the literature, the proposed mechanisms, the available safety information and the UK regulatory framing.

Mechanism of action

The principal proposed mechanism is the same gene-regulatory model applied across the Khavinson short-peptide family. According to Khavinson and colleagues, EDR enters cells and reaches the nucleus, where it binds short DNA sequence motifs in promoter regions and modulates transcription. In Pinealon's case, the target gene profile is reported to favour antioxidant-defence and antiapoptotic genes in neuronal lineages.

In in vitro models of hypoxic and oxidative stress, Pinealon reduces reactive oxygen species accumulation and preserves mitochondrial membrane potential in cultured neurons. The peptide reduces caspase-3 activation and DNA fragmentation under conditions that produce substantial apoptosis in vehicle-treated controls.

In rodent models, intranasal and subcutaneous administration produce measurable effects on hippocampal antioxidant enzyme expression (SOD1, catalase) and on behavioural measures of learning and memory in aged animals. Effects are typically modest but reproducible within the published series.

The gene-regulatory model — short peptides reaching the nucleus and binding DNA directly — remains the most actively debated aspect of Pinealon's pharmacology. Independent replication of the proposed binding motifs in chromatin immunoprecipitation experiments has not been reported outside the original group.

Research history

Pinealon was developed in the 1990s as part of the broader Khavinson cytomedine programme and has been subject to in-house preclinical investigation since. Published work has appeared in Russian-language gerontology journals (Bulletin of Experimental Biology and Medicine, Advances in Gerontology) and in international journals on neuroscience and ageing.

Outside the St Petersburg group, Pinealon is comparatively under-studied. There are no large-scale phase II or III clinical trials registered with the MHRA, EMA or FDA. Interest from the wider longevity research community has grown alongside the broader Khavinson short-peptide programme, but independent reproduction work remains limited.

Summarised studies